Its pharmacological activity resembles that of the oleic acid derivative OEA, which is a well-characterized PPAR-α/GPR119 receptor agonist that is capable of counteracting the metabolic syndrome associated with complicated obesity. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.